Affiliation:
1. Division of Pediatric Hematology/Oncology Weill Cornell Medicine New York New York USA
2. Department of Internal Medicine American University of Beirut Medical Center Beirut Lebanon
3. Cancer and Blood Disease Institute Children's Hospital Los Angeles and USC Keck School of Medicine Los Angeles California USA
4. First Department of Pediatrics National and Kapodistrian University of Athens Athens Greece
5. Fondazione IRCCS Ca’ Granda Policlinico Hospital University of Milan Milan Italy
Abstract
SummaryPatients with transfusion‐dependent β‐thalassaemia require lifelong, regular red blood cell transfusions for survival; however, frequent blood transfusions are associated with an increased risk of iron overload, transfusion‐transmitted disease and alloimmunization, as well as reduced quality of life. Luspatercept, an erythroid maturation agent that promotes late‐stage erythroid maturation independently of erythropoietin, has demonstrated efficacy in reducing transfusion burden in patients with transfusion‐dependent β‐thalassaemia. In this review, we discuss treatment initiation, ongoing evaluation, dose adjustment and management of adverse events in transfusion‐dependent patients with β‐thalassaemia receiving luspatercept, and we provide guidance on how to determine whether patients are deriving clinical benefit.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献